Drugs Regulator
-
{
- All
- News
- Videos
-
Ozempic And Wegovy Weight Loss Eventually Plateaus, Study Explains Why
While semaglutide has shown impressive results in aiding weight loss, many users may experience a plateau after an initial period of significant weight loss.
-
42 Drug Samples Found 'Not Of Standard Quality (NSQ)' In April: Health Ministry
According to routine regulatory surveillance, the list of not of standard quality (NSQ) and spurious drugs is displayed on the CDSCO portal every month.
-
Injectable Cosmetic Products Not Permitted, Drug Regulator Issues Warning
Cosmetic products supplied in injectable form do not fall under the definition of cosmetics under the law and are not permitted for use by consumers, professionals or aesthetic clinics, the central drug regulator has made it clear.
-
Centre Assures No Disruption In Medicine Access Amid Chemists' Strike Call, 12 State Pharmacy Bodies Opt Out
All India Organisation of Chemists and Druggists (AIOCD) on May 20 called a nationwide strike to protest online medical sales and deep discounting by e-pharmacy platforms.
-
Your Genes May Decide How Well Weight Loss Drugs Work: Study
The research suggested that some of the same gene variants associated with better weight loss were also linked to stronger gastrointestinal side effects such as nausea or vomiting.
-
Beyond GLP-1: New 5-In-1 Compound More Effective Than Semaglutide For Diabetes And Weight Loss
This innovative compound is known as a 'quintuple agonist' because it combines the power of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists with lanifibranor.
-
Fake Mounjaro In India: Eli Lilly Issues Tips And Checklist To Identify Fakes
In a significant move to protect consumers, the Haryana State-FDA recently conducted a successful operation in Gurugram, seizing counterfeit products falsely labelled as Mounjaro (tirzepatide).
-
Combining These Two Commonly Prescribed Drugs May Reverse Fatty Liver, Reveals Study
Pemafibrate and Telmisartan are medications primarily used to manage cholesterol and blood pressure, respectively. The study suggests that they may also be highly effective when used together to treat fatty liver disease.
-
Public Health Alert: Rajasthan Bans 7 Sub-Standard Medicines
Jaipur, April 22 (IANS) Prioritising public health and patient safety, the Commissionerate of Food Safety and Drug Control, Rajasthan, has issued an alert regarding seven medicines and declared them “Not of Standard Quality” following laboratory test
-
Fake Weight Loss Injections Are Flooding The Market; Doctors Warn Patients Of Serious Health Risks
Fake weight loss injections are flooding the market, posing serious health risks. Dr Ravi Malik and Dr Shilpa Bhatte explain in depth about the prevalence of fake weight loss injections and how to safeguard yourself.
-
High Cost, Limited Access: How Counterfeit Keytruda Market Puts Cancer Patients At Risk
Keytruda, developed by Merck & Co., belongs to a class of drugs known as immune checkpoint inhibitors, which help the immune system identify and attack cancer cells.
-
New Study Explains Why Ozempic Doesn't Work For Everyone
A new study published in Genome Medicine details that Ozempic doesn't work for everyone in the same manner. Here is what you need to know about its mechanisms and why making science-based medical decisions is important.
-
"Weight-Loss Injections Are Not For Wedding Prep Shortcut", Doctors Warn Against Misuse Of Ozempic, Mounjaro
These medications are designed for people with obesity or related health conditions, not for short-term aesthetic goals. When used by otherwise healthy individuals aiming for quick slimming, the balance between benefit and risk often becomes unfavour
-
With Rs 13,000-25,000 Per Dose, Weight-Loss Drugs Are Changing Indian Weddings For Brides
The lowest Mounjaro injection pen dose sells for Rs 13,125 per month, while the highest dose costs Rs 25,781. Novo is selling the lowest Wegovy dose for Rs 5,660 and the highest for Rs 16,400 a month
-
FDA Approves New Weight-Loss Pill For Use At Any Time Of Day
The US regulator has approved Eli Lilly's new oral weight-loss drug Foundayo through a fast-track process, offering a more convenient and potentially affordable alternative to injectable obesity treatments.
-
Ozempic And Wegovy Weight Loss Eventually Plateaus, Study Explains Why
While semaglutide has shown impressive results in aiding weight loss, many users may experience a plateau after an initial period of significant weight loss.
-
42 Drug Samples Found 'Not Of Standard Quality (NSQ)' In April: Health Ministry
According to routine regulatory surveillance, the list of not of standard quality (NSQ) and spurious drugs is displayed on the CDSCO portal every month.
-
Injectable Cosmetic Products Not Permitted, Drug Regulator Issues Warning
Cosmetic products supplied in injectable form do not fall under the definition of cosmetics under the law and are not permitted for use by consumers, professionals or aesthetic clinics, the central drug regulator has made it clear.
-
Centre Assures No Disruption In Medicine Access Amid Chemists' Strike Call, 12 State Pharmacy Bodies Opt Out
All India Organisation of Chemists and Druggists (AIOCD) on May 20 called a nationwide strike to protest online medical sales and deep discounting by e-pharmacy platforms.
-
Your Genes May Decide How Well Weight Loss Drugs Work: Study
The research suggested that some of the same gene variants associated with better weight loss were also linked to stronger gastrointestinal side effects such as nausea or vomiting.
-
Beyond GLP-1: New 5-In-1 Compound More Effective Than Semaglutide For Diabetes And Weight Loss
This innovative compound is known as a 'quintuple agonist' because it combines the power of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists with lanifibranor.
-
Fake Mounjaro In India: Eli Lilly Issues Tips And Checklist To Identify Fakes
In a significant move to protect consumers, the Haryana State-FDA recently conducted a successful operation in Gurugram, seizing counterfeit products falsely labelled as Mounjaro (tirzepatide).
-
Combining These Two Commonly Prescribed Drugs May Reverse Fatty Liver, Reveals Study
Pemafibrate and Telmisartan are medications primarily used to manage cholesterol and blood pressure, respectively. The study suggests that they may also be highly effective when used together to treat fatty liver disease.
-
Public Health Alert: Rajasthan Bans 7 Sub-Standard Medicines
Jaipur, April 22 (IANS) Prioritising public health and patient safety, the Commissionerate of Food Safety and Drug Control, Rajasthan, has issued an alert regarding seven medicines and declared them “Not of Standard Quality” following laboratory test
-
Fake Weight Loss Injections Are Flooding The Market; Doctors Warn Patients Of Serious Health Risks
Fake weight loss injections are flooding the market, posing serious health risks. Dr Ravi Malik and Dr Shilpa Bhatte explain in depth about the prevalence of fake weight loss injections and how to safeguard yourself.
-
High Cost, Limited Access: How Counterfeit Keytruda Market Puts Cancer Patients At Risk
Keytruda, developed by Merck & Co., belongs to a class of drugs known as immune checkpoint inhibitors, which help the immune system identify and attack cancer cells.
-
New Study Explains Why Ozempic Doesn't Work For Everyone
A new study published in Genome Medicine details that Ozempic doesn't work for everyone in the same manner. Here is what you need to know about its mechanisms and why making science-based medical decisions is important.
-
"Weight-Loss Injections Are Not For Wedding Prep Shortcut", Doctors Warn Against Misuse Of Ozempic, Mounjaro
These medications are designed for people with obesity or related health conditions, not for short-term aesthetic goals. When used by otherwise healthy individuals aiming for quick slimming, the balance between benefit and risk often becomes unfavour
-
With Rs 13,000-25,000 Per Dose, Weight-Loss Drugs Are Changing Indian Weddings For Brides
The lowest Mounjaro injection pen dose sells for Rs 13,125 per month, while the highest dose costs Rs 25,781. Novo is selling the lowest Wegovy dose for Rs 5,660 and the highest for Rs 16,400 a month
-
FDA Approves New Weight-Loss Pill For Use At Any Time Of Day
The US regulator has approved Eli Lilly's new oral weight-loss drug Foundayo through a fast-track process, offering a more convenient and potentially affordable alternative to injectable obesity treatments.
